Following a time period in which Novo Nordisk's biopharma business has had some growth issues, there's light at the end of the tunnel in the view of Novo Nordisk Biopharm's Executive Vice President Ludovic Helfgott, according to Danish newspaper Finans.
He explains that Biopharm's currently most advanced drug candidates – growth hormone somapacitan and hemophilia drugs Mim8 and Concizumab – are all potential blockbusters in his view. By that, he means that they can potentially sell for more than USD 1bn.
"We're delivering incredibly strong growth in the diabetes area, and I am convinced that we can deliver the same growth with our Biopharm products," Helfgott tells Finans.
In 2020, Novo Nordisk's whole biopharma area had a DKK 18.9bn (USD 3.0bn) revenue after going up 1 percent in local currency.
More from MedWatch
Long wait for IVDR implementation is over, putting an end to pandemic "wild west"
After prolonged debates on potential bottlenecking and supply issues, the EU’s long-awaited In Vitro Diagnostic Medical Devices Regulation comes into force on May 26.
GN purchase story is very speculative, says analyst
Competition rules could block a purchase of GN Store Nord and subsequent divestment of GN Hearing, says a Sydbank analyst on the speculative story that this might be underway.
Bavarian Nordic upgrades guidance following vaccine contract
Bavarian has been the center of attention in recent days due to its monkeypox vaccine, and the company has now secured a vaccine contract with another undisclosed country. Consequently, Bavarian has raised its expectations for the full year.
Novo Nordisk invests additional millions of dollars in new manufacturing facilities
Novo Nordisk’s DKK 17bn (USD 2.4bn) investment into upgrading and building new facilities in Kalundborg last year has now been followed by a DKK 1bn (USD 143.8m) investment in the same location.
US to start using Bavarian vaccine stockpile
In an attempt to contain a monkeypox outbreak, US authorities will start offering certain people Bavarian Nordic-developed Jynneos vaccinations against the infectious disease.
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Senior QA Specialist 
Clinical Project Manager 
Production Director 
IRT Manager, Clinical Drug Supply 
Cell Culture Scientist/Senior Scientist 
Senior Project Manager (GMP - Life Science) 
Consultant Manager 
Senior Chemical Safety Advisor 
Chemist for Incoming Materials in QC Department 
Nordic Medical Affairs Manager 
Account Manager 
Project Manager & Scrum Master 
Client Talent Acquisition Specialist 
Innovation Project Manager, Display Unit